Respiratory syncytial virus
Infants and the elderly are particularly affected by severe RSV infections. Vaccines offer protection for the elderly and pregnant women. Phase III data are available for three vaccines: two antigen-based vaccines (already approved) and one mRNA vaccine. Since August 1, 2024, STIKO has been recommending RSV vaccination as standard for all people aged 75 and over – for people aged 60 to 74 with risk factors as an indication for vaccination.